Natera presents colorectal, breast cancer data at ESMO 2022

By staff writers

September 13, 2022 -- Natera on Monday announced data for its molecular residual disease (MRD) test, Signatera, presented in four abstracts at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.

One abstract, related to the Bellini trial, examined the potential clinical utility of circulating tumor DNA (ctDNA) in assessing the response to neoadjuvant immunotherapy in patients with early-stage (I-II) triple-negative breast cancer (TNBC).

Before beginning neoadjuvant chemotherapy, 30 patients were treated with two cycles of the immune checkpoint inhibitor nivolumab, either on its own or in combination with ipilimumab. Those who achieved a partial response presented with 50% to 100% reduction in ctDNA levels compared to pretreatment, while increasing or stable ctDNA levels were observed in non-responders.

"The Bellini trial supports MRD testing for early, reliable immunotherapy response monitoring in the neoadjuvant TNBC setting," Dr. Minetta Liu, Natera's chief medical officer of oncology, said in a statement.

Natera also announced data from a retrospective analysis of how real-world monitoring of ctDNA could predict cancer recurrence in patients with resected stages I-III colorectal cancer (CRC).

The MRD status of 16,347 patients was assessed using the Signatera test after surgery and during surveillance. Postoperative MRD-positive status was significantly associated with inferior recurrence-free survival, while MRD-negative status showed no significant benefit from adjuvant chemotherapy, regardless of other risk factors such as stage, age, or microsatellite instability status.

"Incorporating MRD testing into the standard of care for CRC may better identify the patients with a high risk of recurrence -- enabling timely intervention, while sparing those who would not benefit from unnecessary treatment," Dr. Stacey Cohen of the Fred Hutchinson Cancer Center, who is the study's principal investigator, said in a statement.

Natera also announced data from a proof-of-concept study for detecting ctDNA in rare thyroid cancers. In a separate presentation, the firm described the phase I dose escalation of IMC-F106C, the first PRAME x CD3 ImmTAC bispecific protein, in solid tumors.

Natera files presubmission with FDA for NIPT test
Natera has proactively filed a presubmission with the U.S. Food and Drug Administration (FDA) as part of the Q-Sub process for the firm’s Panorama noninvasive...
Natera to participate in UnitedHealthcare network
Natera on Thursday announced that it has been selected to participate in UnitedHealthcare's Preferred Laboratory Network (PLN), effective July 1.
Natera shines spotlight on clinical study for Renasight
Natera is directing attention to a prospective multicenter clinical trial now underway for its Renasight genetic testing panel in patients with chronic...
Natera highlights Signatera data at AACR
Natera is highlighting results from clinical studies on breast cancer that used its Signatera tumor-informed molecular residual disease test. The findings...
Natera highlights lung donor study results for Prospera test
Natera is highlighting the performance of its Prospera lung donor-derived cell-free DNA test in assessing rejection and allograft injury in lung transplant...

Copyright © 2022

Last Updated mp 9/13/2022 1:09:30 PM